AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18210765
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus metformin
Trial: 12037435
Drug: Low-dose botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose botulinum toxin (BTX) treatment (mean total target dose of 547 +/- 113 mouse units)
Trial: 12037435
Drug: 4-times-diluted preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-times-diluted preparation (130 +/- 32 MU)
Trial: 7486097
Drug: Epidural clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural clonidine (4 micrograms/kg in 10 mL) infused in 20 min followed by a 2-micrograms.kg-1.h-1 infusion (5 mL/h) during 12 h (Group 1)
Trial: 7486097
Drug: Sufentanil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (0.5 microgram/kg in 10 mL) in 20 min followed by a 0.25-microgram.kg-1.h-1 infusion (5 mL/h) during 12 h (Group 2)
Trial: 2137971
Drug: Nafarelin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin, 400 and 800 micrograms administered intranasally
Trial: 2137971
Drug: Danazol, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol, 600 and 800 mg
Trial: 6770408
Drug: Alcohol 0.45
RxNorm normalized name: ALCOHOL 0.45 mL in 1 mL TOPICAL LIQUID [Decolorized Iodine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol 0.45 ml/kg
Trial: 6770408
Drug: Alcohol 0.90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol 0.90 ml/kg
Trial: 6770408
Drug: Combined alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined alcohol (0.45 ml/kg and 0.90 ml/kg) and sleep deprivation (26 h)
Trial: 6770408
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 ml/kg alcohol and no sleep deprivation)
Trial: 30370852
Drug: Fomentex herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fomentex herbal tea 11.2 g/day in 2 divided doses for 2 weeks
Trial: 30370852
Drug: Medroxy progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medroxy progesterone acetate (MP) 10 mg/day for the last 10 days of their menstrual cycles
Trial: 28962586
Drug: Treatment intensification
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment intensification (methotrexate + tapered high-dose prednisone)
Trial: 23665027
Drug: Lixisenatide 20
RxNorm normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 20 μg QD
Trial: 19250050
Drug: Ga‐As laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ga‐As laser therapy combined with a 12‐wk comprehensive home exercise program
Trial: 9814462
Drug: T4 (levothyroxine)
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T4 (levothyroxine) treatment (21 patients, 2.7 +/- 0.3 microg/kg, TSH < 0.3 microIU/mL)
Trial: 9814462
Drug: T4 (levothyroxine)
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T4 (levothyroxine) treatment
Trial: 2473363
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy [3 X (COPP + ABVD)]
Trial: 2473363
Drug: Chemotherapy [1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy [1 X (COPP + ABVD)]
Trial: 28584913
Drug: Triazolam 0.0625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam 0.0625 mg
Trial: 17461726
Drug: (32)P‐chromic phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (32)P‐chromic phosphate colloids (32)P‐CP) administered via multipointed infiltrative injection
Trial: 17461726
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (simple operative group without (32)P‐CP injection)
Trial: 16602632
Drug: Fluvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin treatment for two months
Trial: 7604799
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg once daily for 4 weeks, then 40 mg twice daily for 12 weeks
Trial: 7604799
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg once daily for 4 weeks, then 40 mg once daily for 12 weeks
Trial: 2227077
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ketorolac given orally every 6 h for up to 7 days
Trial: 2227077
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg pentazocine given orally every 6 h for up to 7 days
Trial: 452941
Drug: Mefruside (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefruside (25 mg daily)
Trial: 452941
Drug: Atenolol (100–400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100–400 mg daily)
Trial: 31945586
Drug: Iloprost infusion
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost infusion (1 ng/kg/min)
Trial: 30114658
Drug: oxaliplatin-fluoropyrimidine chemotherapy
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxaliplatin-fluoropyrimidine chemotherapy with cetuximab
Trial: 30114658
Drug: oxaliplatin-fluoropyrimidine chemotherapy
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxaliplatin-fluoropyrimidine chemotherapy
Trial: 20226404
Drug: Laparoscopic cystectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic cystectomy with the vasopressin injection technique
Trial: 20226404
Drug: Ordinary laparoscopic
RxNorm normalized name: ordinary salt combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary laparoscopic cystectomy without injection
Trial: 20226404
Drug: Laparoscopic cystectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic cystectomy with the injection of saline solution
Trial: 19112723
Drug: Metoprolol (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (starting dose 50 mg bid)
Trial: 19112723
Drug: Clonazepam (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (starting dose 0.5 mg qd)
Trial: 16181303
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg (once per day)
Trial: 12719203
Drug: Aspirin (low-risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (low-risk patients)
Trial: 12719203
Drug: Aspirin (validation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (validation set low-risk patients)
Trial: 12719203
Drug: Therapeutic oral
RxNorm normalized name: multivitamin,therapeutic ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic oral anticoagulation therapy (low-risk patients)
Trial: 8723141
Drug: FCE 23,884
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCE 23,884 monotherapy (3.5 +/- 0.5 mg)
Trial: 8723141
Drug: FCE 23,884
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCE 23,884 coadministered with a mildly dyskinetic dose of levodopa
Trial: 6685515
Drug: standard oxazepam
RxNorm normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard oxazepam formulation
Trial: 29344631
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) - 12 sessions, 60 minutes each
Trial: 29344631
Drug: Written Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written Exposure Therapy (WET) - 5 sessions, 60 minutes for the first session and 40 minutes for the remaining sessions
Trial: 22431582
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust exposure (200 μg/m(3) of fine particulate matter) for 120 minutes
Trial: 17997151
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 300 mg tenofovir disoproxil fumarate with 200 mg emtricitabine
Trial: 15486039
Drug: Ketorolac (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (45 mg)
Trial: 12214151
Drug: 10-20 mg
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-20 mg quinapril for 6 months
Trial: 12214151
Drug: 50-100 mg
RxNorm normalized name: insulin lispro protamine, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-100 mg losartan for 6 months
Trial: 26646828
Drug: Metacognitive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacognitive therapy programme
Trial: 16943462
Drug: Palamed G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palamed G
Trial: 10809243
Drug: Immediate full-volume
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate full-volume exchange (2000 mL) per 6 hours from the day of catheter implantation (group 2)
Trial: 1516840
Drug: cold perfusate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cold perfusate + EC‐SOD C 10.4 mg/L (30,000 U/L)
Trial: 1516840
Drug: cold perfusate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cold perfusate + bovine CuZn‐SOD 7.5 mg/L (30,000 U/L)
Trial: 1516840
Drug: cold perfusate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cold perfusate + EC‐SOD C 10.4 mg/L + heparin 50,000U/L
Trial: 1516840
Drug: cold perfusate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cold perfusate + heparin 50,000 U/L
Trial: 1516840
Drug: cold perfusate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cold perfusate only, cold perfusate + bovine CuZn‐SOD, cold perfusate + EC‐SOD C + heparin, cold perfusate + heparin
Trial: 6707844
Drug: Full-strength cow's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-strength cow's milk feeds after 24 hours of GEM treatment
Trial: 28857654
Drug: Duloxetine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine therapy for 12 weeks
Trial: 15041596
Drug: Preincision ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preincision ketamine 0.15 mg/kg
Trial: 15041596
Drug: Postoperative ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative ketamine 0.15 mg/kg
Trial: 7942164
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1000 or 2000 mg Ca2+)
Trial: 2904754
Drug: Doxazosin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (mean dose, 3.3 mg) once daily for 8 weeks
Trial: 2904754
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg) once daily for 8 weeks
Trial: 26758116
Drug: Methylprednisolone 2
RxNorm normalized name: methylprednisolone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 2 mg/(kg·d) intravenously for 3 days
Trial: 26758116
Drug: Non-steroid therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroid therapy
Trial: 22028266
Drug: Fendrix (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fendrix (20 micrograms, 4 doses)
Trial: 22028266
Drug: Engerix B
RxNorm normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix B (40 micrograms, 3 doses with optional booster)
Trial: 11185674
Drug: Rofecoxib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (50 mg QD for 10 days)
Trial: 11185674
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg once daily on days 4 through 10) with Rofecoxib
Trial: 2860386
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg CL115,347/day transdermally for 6 weeks
Trial: 30624598
Drug: 6-month hypocaloric,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month hypocaloric, nutritionally complete, higher-protein meal plan targeting ≥1.0 g protein · kg body weight-1 · d-1 (WL group; n=47)
Trial: 30624598
Drug: Weight-stability (WS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-stability (WS) group targeting 0.8 g protein · kg body weight-1 · d-1 (n=49)
Trial: 26993331
Drug: C. difficile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. difficile vaccine formulations (toxoids A and B) administered at antigen dose levels of 50, 100, or 200 μg in a 3-dose regimen at 0, 1, and 6 months.
Trial: 22782417
Drug: Acadesine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acadesine (0.1 mg/kg per minute for 7 hours)
Trial: 21311486
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (copaxone) 20 mg/d for 4.3±2.6 years
Trial: 21311486
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with confirmed MS in remission not treated with disease-modifying drugs
Trial: 10332798
Drug: Passive control
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive control treatment
Trial: 2044395
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg bencyclane twice daily
Trial: 28644575
Drug: Levofloxacin plus
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin plus bismuth‐based quadruple therapy (RBAL)
Trial: 28644575
Drug: Levofloxacin‐based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin‐based triple therapy (RAL)
Trial: 23984728
Drug: Macitentan 3
RxNorm normalized name: Macitentan
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Macitentan 3 mg
Trial: 16860698
Drug: Non-nucleoside reverse
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nucleoside reverse transcriptase inhibitor (efavirenz, EFV)
Trial: 16860698
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor (nelfinavir, NFV)
Trial: 12664518
Drug: Oral Tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tramadol 0.5 mg/kg/6 hours for 24 hours
Trial: 12664518
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (32 children with one dose of Tramadol 2 mg/kg)
Trial: 1108694
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of 20-25 ml of normal saline
Trial: 7406657
Drug: Dextroamphetamine sulfate
RxNorm normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine sulfate (single oral dose)
Trial: 28343801
Drug: ONS (Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONS (Oral Nutritional Supplements)
Trial: 21883811
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide (1 g 12-h)
Trial: 18635696
Drug: SL65.1498 (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SL65.1498 (three doses)
Trial: 17244295
Drug: Directly hired
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly hired workers (treatment group)
Trial: 9800063
Drug: Conventional daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional daily wear soft contact lenses
Trial: 25223369
Drug: Remogliflozin etabonate
RxNorm normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remogliflozin etabonate (RE) 50, 100, 250, 500 or 1000 mg twice daily
Trial: 17084549
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg twice daily) with concurrent cisplatin (75 mg/m2) and 5-FU (1g/m2 for 4 days) and pelvic radiation therapy
Trial: 9876503
Drug: Phenylbutazone tablets
RxNorm normalized name: Phenylbutazone Tablets
DrugBank: Phenylbutazone (DB00812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylbutazone tablets
Trial: 8011009
Drug: Multiple-unit formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-unit formulation (Diclo-Puren 50)
Trial: 8011009
Drug: Single-unit formulation
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-unit formulation (reference)
Trial: 2575369
Drug: Cicletanine 50
RxNorm normalized name: cicletanine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine 50 mg/day and Cicletanine 100 mg/day
Trial: 1190365
Drug: Metronidazole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (2.5 g during 5 days to 7.5 g in 10 days for children; 5 g in 5 days or 12.5 g in 10 days for adults)
Trial: 25974235
Drug: Mesenchymal stem
RxNorm normalized name: Human mesenchymal stem cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stem cell therapy
Trial: 29888663
Drug: Dental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental treatment during pregnancy
Trial: 23774238
Drug: Sivelestat (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sivelestat (0.2 mg/kg/hour continuous intravenous infusion)
Trial: 16894407
Drug: Tramadol Contramid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol Contramid once-daily 200 mg tablets
Trial: 16894407
Drug: Zytram 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zytram 200 mg tablets
Trial: 12509627
Drug: Doloteffin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doloteffin (60 mg of harpagoside daily for 6 weeks)
Trial: 12509627
Drug: Rofecoxib (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (12.5 mg/day for 6 weeks)
Trial: 8706482
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg administered intravenously)
Trial: 8706482
Drug: Placebo (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equivalent administered intravenously)
Trial: 1714011
Drug: ISDN +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN + NAC (600 mg q.i.d.)
Trial: 6178382
Drug: Clorgyline, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorgyline, 5 to 10 mg every or every other day
Trial: 10967698
Drug: Prazosin (sustained-release)
RxNorm normalized name: prazosin Extended Release Oral Tablet
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prazosin (sustained-release) 2.5 mg
Trial: 8790198
Drug: 111In‐CYT‐103 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 111In‐CYT‐103 (150 MBq; 1 mg)
Trial: 8218966
Drug: Intramuscular tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular tenoxicam (20 mg)
Trial: 8218966
Drug: Oral tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tenoxicam (20 mg)
Trial: 28628251
Drug: Single-drug regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-drug regimens (Vemurafenib, Dabrafenib, Nivolumab)
Trial: 28628251
Drug: Double-drug regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-drug regimens (Dabrafenib + Trametinib, Nivolumab + Ipilimumab, Vemurafenib + Cobimetinib)
Trial: 28628251
Drug: Single-drug regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-drug regimens (Vemurafenib, Dabrafenib)
Trial: 28628251
Drug: Double-drug regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-drug regimens (Dabrafenib + Trametinib, Vemurafenib + Cobimetinib)
Trial: 27368882
Drug: Adjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormonal therapy and breast surgery
Trial: 24673050
Drug: Acupoint catgut
RxNorm normalized name: CATGUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint catgut implantation combined with artificial periodic therapy
Trial: 24673050
Drug: Artificial periodic
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial periodic therapy with oral administration of medroxyprogesterone acetate tablets
Trial: 20973708
Drug: Ritalin(®) LA
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ritalin(®) LA 20 mg
Trial: 15582637
Drug: Reminiscence intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reminiscence intervention (weekly for 4 months)
Trial: 12397268
Drug: Carbohydrate-electrolyte rehydration
RxNorm normalized name: CARBOHYDRATE/ELECTROLYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-electrolyte rehydration solution
Trial: 8978228
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment need
Trial: 8978228
Drug: Treatment by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment by prison health care services